ANI Pharmaceuticals vs Indivior
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put ANI Pharmaceuticals and Indivior side by side, using each oneβs latest annual report. Here is what stands out:
- Indivior is the larger business, with $1.2B of revenue in fiscal 2025 against $883M for ANI Pharmaceuticals.
- ANI Pharmaceuticals grew revenue faster (43.8%, against 4.3%).
- Indivior kept more of each dollar of sales as operating profit (21.2% operating margin, against 12.6%).
- ANI Pharmaceuticals turned more of its sales into free cash flow (19.4% FCF margin, against β7.5%).
- Investors pay more for each dollar of ANI Pharmaceuticalsβs earnings: a P/E of 15.7x against 12.4x for Indivior.
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
ANI Pharmaceuticals
ANIP
4/7
Revenue growthFCF marginPiotroski F-scoreNet debt / EBITDA
Indivior
INDV
3/7
Operating marginNet marginShare count change
Side by side
Best in the row
| Latest fiscal year | ANIP FY25 | INDV FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.6B | $4.3B |
| Revenue | $883M | $1.2B |
| Free cash flow | $171M | β$93.0M |
| Net income | $78.3M | $210M |
| Growth | ||
| Revenue growth | 43.8% | 4.3% |
| 5-year growth | 33.5% | β |
| Share count change | 9.9% | β3.8% |
| Profitability | ||
| Gross margin | β | 80.2% |
| Operating margin | 12.6% | 21.2% |
| Net margin | 8.9% | 17.0% |
| FCF margin | 19.4% | β7.5% |
| Return on capital | 15.9% | β |
| Return on equity | 16.6% | β |
| Balance sheet | ||
| Net debt | $23.7M | $124M |
| Net debt / EBITDA | 0.1x | 0.5x |
| Dividends and buybacks | $13.4M | $11.0M |
| Valuation & quality | ||
| P/E | 15.7x | 12.4x |
| Piotroski F-score | 6 | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.